NovaBridge Biosciences (NBP) Receivables (2020 - 2022)

NovaBridge Biosciences (NBP) has reported Receivables for 3 consecutive years, with $1.2 million the latest figure, recorded in Q4 2022.

• In Q4 2022, Receivables fell 100.0% year-over-year to $1.2 million; the TTM figure through Dec 2022 stood at $1.2 million (down 100.0% YoY), while the FY2022 annual figure was $1.2 million, down 100.0% from the prior year.
• Receivables fell to $1.2 million in Q4 2022 per NBP's latest filing, from $49.8 million in the prior quarter.
• Across five years, Receivables topped out at $39.7 billion in Q4 2021 and bottomed at $1.2 million in Q4 2022.
• Historically, Receivables has averaged $8.0 billion across 3 years, with a median of $42.2 million in 2020.
• Annual changes were most pronounced in 2021 — Receivables jumped 94062.61% — and 2022, when it tumbled 100.0%.
• NovaBridge Biosciences' Receivables stood at $42.2 million in 2020, then surged by 94062.61% to $39.7 billion in 2021, then slumped by 100.0% to $1.2 million in 2022.
• Business Quant data shows NBP's Receivables at $1.2 million in Q4 2022, $49.8 million in Q2 2022, and $39.7 billion in Q4 2021.